Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2022 | 1 |
2023 | 1 |
2024 | 0 |
Search Results
2 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial.
Lancet Gastroenterol Hepatol. 2022 Apr;7(4):294-306. doi: 10.1016/S2468-1253(21)00474-X. Epub 2022 Feb 1.
Lancet Gastroenterol Hepatol. 2022.
PMID: 35120656
Clinical Trial.
Ustekinumab improves health-related quality of life in patients with moderate-to-severe Crohn's disease: Results up to Week 104 of the STARDUST trial.
Panés J, Vermeire S, D'Haens GR, Danese S, Magro F, Nazar M, Le Bars M, Lahaye M, Ni L, Bravatà I, Gaya DR, Peyrin-Biroulet L, Dignass A; STARDUST study group.
Panés J, et al.
United European Gastroenterol J. 2023 Jun;11(5):410-422. doi: 10.1002/ueg2.12384. Epub 2023 May 4.
United European Gastroenterol J. 2023.
PMID: 37139642
Free PMC article.
Clinical Trial.
Item in Clipboard
Cite
Cite